Barinthus Biotherapeutics (BRNS) Non-Current Deferred Tax Liability (2023 - 2026)

Barinthus Biotherapeutics has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $237000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 43.03% year-over-year to $237000.0; the trailing twelve-month figure through Mar 2026 stood at $237000.0 (down 43.03% YoY), and the FY2025 full-year result was $254000.0, down 97.52% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $237000.0, down from $254000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $11.8 million in Q4 2023, with the low at $237000.0 in Q1 2026.
• Historically, Non-Current Deferred Tax Liability has averaged $3.0 million across 4 years, with a median of $403500.0 in 2025.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability retreated 12.76% — and 2025, when it tumbled 97.52%.
• Barinthus Biotherapeutics' Non-Current Deferred Tax Liability stood at $11.8 million in 2023, then slipped by 12.76% to $10.3 million in 2024, then plunged by 97.52% to $254000.0 in 2025, then retreated by 6.69% to $237000.0 in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $237000.0 (Q1 2026), $254000.0 (Q4 2025), and $320000.0 (Q3 2025), per Business Quant data.